{"id":"64714d8eec4a","type":"article","url":"https://hartvaat.nl/2026/02/01/therapeutische-innovaties-in-de-secundaire-preventie-van-cardiovasculair-risico/","title":"Therapeutische innovaties in de secundaire preventie van cardiovasculair risico","title_en":"[Therapeutic innovations in secondary prevention of cardiovascular risk].","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["acuut-hartfalen","aspirine","bempedoïnezuur","biomarkers-cardiovasculair","cardiorenal-behandelstrategie","cetp-remmers","clear-outcomes","colchicine","diabetes-en-hart","diabetes-type-2","dyslipidemie","enlicitide","ezetimibe","farmaco-economie","figaro-dkd","gepersonaliseerde-geneeskunde","glp1-agonisten","hartrevalidatie","hdl-cholesterol","inflammatie","ldl-cholesterol","lipide-aferese","lipidenverlaging","lipoproteïne-a","lipoproteïne-a-therapeutisch-doel","menopauze","microbioom","niet-statine-therapie","obesitas","ouderen","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","pelacarsen","plaquekarakterisatie","ramipril","richtlijnen-esc","roken","secundaire-preventie","slaapapneu","statines","trombocytenaggregatieremmers","voeding-hart"],"journal":"La Revue du praticien","doi":"https://pubmed.ncbi.nlm.nih.gov/41732931/","source_url":"https://doi.org/https://pubmed.ncbi.nlm.nih.gov/41732931/","authors":["Franck Boccara"],"significance":4,"published":"2026-02-01","source_date":"2026-02-01","image":"https://hartvaat.nl/global/img/0ef5024189ff.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/inflammatie-en-atherosclerose/","https://hartvaat.nl/kennis/lipiden/lp-a-verhoogd/"],"congress":"","summary_en":"This review discusses therapeutic innovations in secondary cardiovascular prevention including PCSK9 inhibitors, inclisiran, bempedoic acid, Lp(a)-targeting RNA therapies, individualised antithrombotic strategies, and low-dose colchicine as anti-inflammatory therapy.","created":"2026-07-03T10:25:05Z","updated":"2026-07-03T13:24:32Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit overzicht bespreekt nieuwe lipidenverlagende therapieën (PCSK9-remmers, inclisiran, bempedoïnezuur), lipoproteïne(a) als nieuw doelwit (pelacarsen, olpasiran), geïndividualiseerde antitrombotica en lage dosis colchicine als anti-inflammatoire strategie bij secundaire cardiovasculaire preventie.","abstract_original":"New lipid-lowering therapies (injectable and oral PCSK9 inhibitors, inclisiran, bempedoic acid) allow more intensive LDL-C reduction, including in statin-intolerant patients.Lipoprotein(a) is emerging as a specific target, with ASO/siRNA agents (pelacarsen, olpasiran, lepodisiran) achieving marked reductions while outcome data are pending.Antithrombotic strategies are now tailored to ischemic and bleeding risks, using shortened dual antiplatelet therapy (DAPT), P2Y12 monotherapy and de-escalation approaches. On the inflammatory side, low-dose colchicine offers a simple, low-cost option for selected coronary patients, though recent results are mixed.Remote monitoring, hybrid cardiac rehabilitation and personalized care pathways help to further reduce residual cardiovascular risk."}